Cytosorbents Corp Stock OTC Bulletin Board
Stocks
CTSO
US23283X1072
Advanced Medical Equipment & Technology
| Market Cap | 32.54M 28.29M 26M 24.47M 45.85M 3.08B 46.39M 309M 120M 1.51B 122M 119M 5.22B | P/E 2026 * |
-2.58x | P/E 2027 * | 15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 32.54M 28.29M 26M 24.47M 45.85M 3.08B 46.39M 309M 120M 1.51B 122M 119M 5.22B | EV / Sales 2026 * |
0.85x | EV / Sales 2027 * | 0.69x |
| Free-Float |
85.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytosorbents Corp
| 1 day | -6.91% |
| Manager | Title | Age | Since |
|---|---|---|---|
Phillip Chan
CEO | Chief Executive Officer | 55 | 2008-07-23 |
Peter Mariani
DFI | Director of Finance/CFO | 62 | 2024-08-13 |
Vincent Capponi
PSD | President | 68 | 2020-04-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Edward Jones
BRD | Director/Board Member | 77 | 2011-07-24 |
Phillip Chan
BRD | Director/Board Member | 55 | 2008-12-31 |
Alan Sobel
BRD | Director/Board Member | 65 | 2014-11-12 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.91% | -.--% | - | - | 32.54M | |
| -2.31% | -6.55% | +13.98% | -14.07% | 176B | |
| -3.57% | -5.73% | -22.51% | +22.11% | 148B | |
| -1.98% | -5.65% | -11.61% | -26.48% | 128B | |
| -4.20% | -8.19% | -55.71% | -17.25% | 69.74B | |
| -2.14% | -0.98% | +15.85% | -5.72% | 51B | |
| -1.84% | -1.25% | -24.74% | -34.38% | 45.7B | |
| -3.12% | -8.23% | +4.46% | +2.64% | 36.25B | |
| -0.98% | -3.81% | +2.64% | +32.62% | 35.4B | |
| -3.29% | -7.36% | -16.07% | -22.25% | 28.76B | |
| Average | -2.31% | -2.78% | -10.41% | -6.98% | 79.84B | |
| Weighted average by Cap. | -1.26% | -3.05% | -9.43% | -7.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.26M 33.27M 30.58M 28.78M 53.92M 3.62B 54.56M 363M 141M 1.77B 144M 141M 6.14B | 47.12M 40.97M 37.66M 35.45M 66.41M 4.45B 67.19M 448M 174M 2.18B 177M 173M 7.56B |
| Net income | -11.74M -10.21M -9.38M -8.83M -16.55M -1.11B -16.74M -112M -43.3M -544M -44.06M -43.12M -1.88B | 2.37M 2.06M 1.9M 1.78M 3.34M 224M 3.38M 22.54M 8.75M 110M 8.91M 8.72M 381M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
